Comparison of outcomes after <scp>DA</scp> ‐ <scp>EPOCH</scp> ‐R or <scp>GMALL</scp> high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort
In this retrospective cohort of adult Burkitt lymphoma, DA-EPOCH-R showed no signal of inferior survival or relapse risk compared with GMALL-based high-intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Authors
- Florian Posch (ORCID: https://orcid.org/0000-0002-0448-6314)
- Eduard Schulz (ORCID: https://orcid.org/0000-0002-6672-4592)
- Kristina Friedrich
- Peter Neumeister (ORCID: https://orcid.org/0000-0002-2761-5334)
- Katharina T. Prochazka
Institutions
- Medical University of Graz (AT)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-07-25
- DOI
- https://doi.org/10.1111/bjh.70730
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00